Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Maio(University of Siena), Brigitte Dréno(Nantes Université), Ana Arance(Hospital Clínic de Barcelona), Gabriella Liszkay(National Institute of Oncology), Delphine Hennicken(Inova Fairfax Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael Smylie(Inserm), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Virginia Ferraresi(Cancer Institute (WIA)), Dirk Schadendorf(National Center for Tumor Diseases), Joanna Pikiel(Chemotherapy Foundation), Inge Marie Svane(Copenhagen University Hospital), Christoph Höeller(Medical University of Vienna), Catriona M. McNeil(Chris O’Brien Lifehouse), Lars Bastholt(Odense University Hospital), Florent Grange(Hôpital Lyon Sud), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Carmen Loquai(Johannes Gutenberg University Mainz), Laurent Mortier, L. Thomas(University of Liverpool), Caroline Robert(Institut Gustave Roussy), Anila Qureshi(Bristol-Myers Squibb (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Jean-Jacques Grob(Aix-Marseille Université), Claus Garbe(University of Tübingen)

The Lancet Oncology

March 27, 2017

Cited by 501

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2013|3.4k

Related Papers